Antibodies Targeting Alpha-Synuclein Epitopes for Lewy Body Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies are ineffective in addressing the accumulation of alpha-synuclein protein, leading to neuronal degeneration and cognitive impairment, as existing therapies fail to target the intracellular nature of Lewy bodies effectively.
Innovation Solution
Administration of antibodies specifically binding to epitopes within alpha-synuclein, such as residues 118-126, to induce an immunogenic response, either actively with immunogens or passively with antibodies, to reduce the number of inclusions in the brain, thereby treating or preventing Lewy body diseases like Parkinson's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used, then treatment of neurodegenerative diseases is attempted, but they fail to effectively target intracellular Lewy bodies and reduce alpha-synuclein aggregation
Solution Approach 1:
The patent employs antibodies as intermediary molecules that specifically bind to alpha-synuclein epitopes (such as residues 118-126). These antibodies act as mediators between the immune system and the pathogenic alpha-synuclein aggregates, enabling targeted recognition and clearance of Lewy bodies without requiring direct penetration into intracellular spaces. The antibodies facilitate immune-mediated removal of the harmful aggregates.
2Reliability
If antibodies are administered to induce immunogenic response, then alpha-synuclein deposits are targeted and cleared, but the complexity of the treatment approach increases
Solution Approach 1:
The patent leverages the body's own immune system to perform the therapeutic function. By administering antibodies that induce an immunogenic response, the treatment activates the patient's endogenous immune mechanisms to recognize, target, and clear alpha-synuclein deposits. This self-service approach eliminates the need for complex external intervention systems while achieving effective clearance of pathological aggregates.
3Ease of operation
If conventional treatments are used, then general symptom management is attempted, but they do not address the root cause of neuronal degeneration
Solution Approach 1:
The patent extracts and specifically targets the root pathological element - alpha-synuclein aggregates - from the complex disease process. By designing antibodies that specifically bind to epitopes on alpha-synuclein, the treatment isolates and removes the causative agent of neuronal degeneration. This extraction approach addresses the fundamental cause rather than merely managing downstream symptoms, while the antibody-based mechanism remains operationally straightforward.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces alpha-synuclein aggregation and Lewy body formation, improving motor and cognitive symptoms in patients by generating a beneficial immune response that targets and clears alpha-synuclein deposits within neurons.
Implementation Method 1
Administration of antibodies specifically binding to epitopes within alpha-synuclein, such as residues 118-126, to induce an immunogenic response
Data Source
Figure 1
Figure 2
Figure 3A~3D
AI summary
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.